ir.regulusrx.comOverview - Regulus Therapeutics
ir.regulusrx.com Profile
Ir.regulusrx.com is a subdomain of regulusrx.com, which was created on 2007-01-03,making it 17 years ago.
Discover ir.regulusrx.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
ir.regulusrx.com Information
| HomePage size: 27.003 KB |
| Page Load Time: 0.980581 Seconds |
| Website IP Address: 104.17.203.159 |
ir.regulusrx.com Similar Website
| Aratana Therapeutics Investor Overview |
| Join the Spark Team – Spark Therapeutics |
| Avenue Therapeutics, Inc. (ATXI) |
| Viridian Therapeutics, Inc. - Investors & Media |
| Clinical Pharmacology and Therapeutics Jobs - American Society for Clinical Pharmacology and Therape |
| Homepage | Drug and Therapeutics Bulletin |
| Amicus Therapeutics to Announce Full-Year 2019 Financial |
| Nutritional Supplements | Integrative Therapeutics |
| Investor Relations :: Checkpoint Therapeutics, Inc. (CKPT) |
| Investor Relations | TG Therapeutics, Inc. |
| Investors | Horizon Therapeutics plc |
| Home | Journal of Pharmacology and Experimental Therapeutics |
| Acorda Therapeutics Grant Application Portal |
| Investor Overview | Mateon Therapeutics |
ir.regulusrx.com PopUrls
| Regulus Therapeutics: Overview https://ir.regulusrx.com/ |
| Press Releases https://ir.regulusrx.com/press-releases |
| Events and Presentations https://ir.regulusrx.com/events |
| Quarterly Results https://ir.regulusrx.com/quarterly-results |
| Investors - Regulus Therapeutics - Fundamentals https://ir.regulusrx.com/fundamentals |
| Investor FAQs https://ir.regulusrx.com/investor-faqs |
| Investor Alerts https://ir.regulusrx.com/alerts |
| SEC Filings https://ir.regulusrx.com/sec-filings |
| Insider Transactions https://ir.regulusrx.com/insider-transactions |
| Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial ... https://ir.regulusrx.com/2024-03-21-Regulus-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Recent-Updates |
| Regulus Therapeutics Reports Fourth Quarter and Year-End 2021 Financial ... https://ir.regulusrx.com/2022-03-10-Regulus-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2021-Financial-Results-and-Recent-Updates |
| Regulus Therapeutics Reports First Quarter 2022 Financial Results and ... https://ir.regulusrx.com/2022-05-12-Regulus-Therapeutics-Reports-First-Quarter-2022-Financial-Results-and-Recent-Updates |
| Regulus Therapeutics Announces First Subject Dosed in Phase 1 Single ... https://ir.regulusrx.com/2022-06-13-Regulus-Therapeutics-Announces-First-Subject-Dosed-in-Phase-1-Single-Ascending-Dose-SAD-Clinical-Trial-of-RGLS8429 |
| Regulus Therapeutics Announces Strategic Prioritization of RGLS8429 ... https://ir.regulusrx.com/2021-10-12-Regulus-Therapeutics-Announces-Strategic-Prioritization-of-RGLS8429,-its-Next-Generation-Candidate-for-the-Treatme |
| Regulus Therapeutics Announces Positive Topline Data from the First ... https://ir.regulusrx.com/2023-09-20-Regulus-Therapeutics-Announces-Positive-Topline-Data-from-the-First-Cohort-of-Patients-in-its-Phase-1b-Multiple-As |
ir.regulusrx.com Httpheader
| Date: Tue, 14 May 2024 19:03:45 GMT |
| Content-Type: text/html; charset=UTF-8 |
| Transfer-Encoding: chunked |
| Connection: keep-alive |
| X-Frame-Options: SAMEORIGIN |
| Strict-Transport-Security: max-age=31536000; includeSubDomains |
| Cache-Control: public, no-cache |
| Vary: Accept-Encoding |
| CF-Cache-Status: EXPIRED |
| Last-Modified: Tue, 14 May 2024 18:10:05 GMT |
| Server: cloudflare |
| CF-RAY: 883d266a9c87642c-SJC |
ir.regulusrx.com Meta Info
| charset="utf-8"/ |
| content="ie=edge" http-equiv="x-ua-compatible"/ |
| content="width=device-width, initial-scale=1.0" name="viewport"/ |
| content="" name="keywords" |
| content="" name="description" |
| content="summary" name="twitter:card" |
| content="Investors - Regulus Therapeutics" property="og:site_name"/ |
| content="https://ir.regulusrx.com/overview" property="og:url"/ |
ir.regulusrx.com Html To Plain Text
TECHNOLOGY Overview Mechanism of Action Pipeline ADPKD PATIENTS INVESTORS Overview Press Releases Events and Presentations Financials & Filings SEC Filings Quarterly Results Corporate Governance Governance Documents Board of Directors Committee Composition Analyst Coverage Stock Information Historical Stock Price Investment Calculator Insider Transactions Fundamentals Form 8937 Investor FAQs Contact Us CAREER INVESTORS . Regulus aims to develop novel oligonucleotide therapeutics that are designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. Home Page Ticker NASDAQ RGLS Latest Quarter . Press Release 10-Q PresentationSee all Quarterly Results Press Releases . Investor Alerts May 09, 2024 Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates Initiated the fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Topline... May 06, 2024 Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today... April 30, 2024 Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today... More press releases Events . Canaccord Genuity Genetic Medicine for Generalists Webcast Series featuring Regulus Therapeutics (RGLS)| Hosted by Whitney Ijem Wednesday, May 1, 2024 1:00pm - 2:00pm EDT Regulus Special Update Call Tuesday, March 12, 2024 8:30am - 9:30am EDT 6th Annual Evercore ISI HealthCONx Conference Wednesday, November 29, 2023 10:25am EST More events upcoming event . No events to display more events corporate presentation . Download (2.9 MB) email alerts . Sign up for email alerts to receive the latest financial information from Regulus Therapeutics Inc. Sign Up IR contact . Phone: 858-202-6300 Email: ir@regulusrx.com Contact Us Copyright 2024 Regulus Therapeutics †All rights reserved Terms and...
ir.regulusrx.com Whois
Domain Name: REGULUSRX.COM Registry Domain ID: 737920093_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2024-01-04T18:18:37Z Creation Date: 2007-01-03T21:42:22Z Registry Expiry Date: 2029-01-03T21:42:22Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS51.DOMAINCONTROL.COM Name Server: NS52.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T20:57:17Z <<<